HOME >> MEDICINE >> NEWS
New discovery may revolutionize treatment for pain related to surgery, illness and injury

For those suffering from pain, scientists from UCLA and the University of Cambridge, United Kingdom, report a revolutionary advance in pain medicine that promises to deliver painkillers directly to the affected area of the body, in smaller doses and with fewer side effects.

The researchers report the first clinically suitable method using nerves as a means of safely delivering high doses of painkillers to achieve a therapeutic effect. They announced their research findings at the Society for Neuroscience conference on Nov. 8 in New Orleans, La.

UCLA neurosurgeon Aaron Filler and his colleagues used a method called "axonal transport" to deliver a pain drug to the spinal ganglia and spinal cord, using nerves as a conduit, in an animal model.

Axonal transport works like a "conveyor-belt" process, delivering pain-relieving medication to remote sensory endings in the tissues of the body. In axonal transport, the cell moves molecules from one end of the cell to the other, thus supporting their ability to communicate with other neurons. A single neuron may be more than two feet long.

Although axonal transport has played a role in thousands of research studies in the past, this is the first-ever report of a positive clinical effect with a potential human medication. The new technology uses a novel molecular structure to achieve clinically effective dosing in targeted groups of nerves, Filler said.

This work marks an important advance, because drug treatment of nervous-system disorders is often hindered and sometimes precluded when the precise site of the injury or disease cannot be reached with adequate levels of pain medicine without causing unwanted side effects. Delivery of painkillers directly to selected target sites can avoid undesired toxicity, as well as inappropriate side effects in non-target neural tissue.

Filler says that with this new method of delivering pain medication, one shot administered during surgery coul
'"/>

Contact: Roxanne Yamaguchi Moster
roxannem@support.ucla.edu
310-794-2264
University of California - Los Angeles
7-Nov-2000


Page: 1 2 3

Related medicine news :

1. TB Alliance announces new drug discovery program with GlaxoSmithKline
2. Mayo Clinic discovery on nature of rheumatoid arthritis lung disease may offer patients therapy
3. Canadian researchers important discovery in HIV research
4. Long-sought key to hearing may be found in protein discovery
5. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
6. Lupus discovery may pave way to better-designed COX-2 inhibitors
7. New discovery may lead to therapy for incurable blood cancer
8. DuPont-led scientists unveil key nanotechnology discovery with use of DNA
9. Canadian discovery promises treatment for HIV dementia
10. Ann Arbor chemist wins national award for drug discovery
11. Zebrafish: Drug discovery of a different stripe holds promise in COX research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: